Evidence map›Paper›PMID 31554376›Full record

Trial reportAsian Pacific journal of cancer prevention : APJCP2019

Clinical and Hematological Relevance of JAK2V617F, CALR, and MPL Mutations in Vietnamese Patients with Essential Thrombocythemia.

Hoang Anh Vu, Tran Thi Thao, Cao Van Dong, Nguyen Lam Vuong, Ho Quoc Chuong, Phan Nguyen Thanh Van, Huynh Nghia, Nguyen Tan Binh, Phu Chi Dung, Phan Thi Xinh

Open access · goldAbstract readClinical Trial
In one paragraph

Trial report in Asian Pacific journal of cancer prevention : APJCP, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.6field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Hoang Anh VuCenter for Molecular Biomedicine, University of Medicine and Pharmacy at Ho Chi Minh City, Ho Chi Minh City, Vietnam.
Tran Thi ThaoDepartment of Hematology, Faculty of Medicine, University of Medicine and Pharmacy at Ho Chi Minh City, Ho Chi Minh City, Vietnam. Email:bsphanthixinh@ump.edu.vn
Cao Van DongHo Chi Minh City Blood Transfusion and Hematology Hospital, Ho Chi Minh City, Vietnam.
Nguyen Lam VuongDepartment of Medical Statistics and Informatics, Faculty of Public Health, University of Medicine and Pharmacy at Ho Chi Minh City, Ho Chi Minh City, Vietnam.
Ho Quoc ChuongCenter for Molecular Biomedicine, University of Medicine and Pharmacy at Ho Chi Minh City, Ho Chi Minh City, Vietnam.
Phan Nguyen Thanh VanHo Chi Minh City Blood Transfusion and Hematology Hospital, Ho Chi Minh City, Vietnam.
Huynh NghiaDepartment of Hematology, Faculty of Medicine, University of Medicine and Pharmacy at Ho Chi Minh City, Ho Chi Minh City, Vietnam. Email:bsphanthixinh@ump.edu.vn
Nguyen Tan BinhHo Chi Minh City Blood Transfusion and Hematology Hospital, Ho Chi Minh City, Vietnam.
Phu Chi DungHo Chi Minh City Blood Transfusion and Hematology Hospital, Ho Chi Minh City, Vietnam.
Phan Thi XinhDepartment of Hematology, Faculty of Medicine, University of Medicine and Pharmacy at Ho Chi Minh City, Ho Chi Minh City, Vietnam. Email:bsphanthixinh@ump.edu.vn
Ho Chi Minh City Medicine and Pharmacy University · VNHCMC Hospital of Dermato Venereology · VN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The picture of Vietnamese patients with essential thrombocythemia (ET) remains mostly undetermined. Our study intended to determine the frequency of JAK2V617F, CALR exon 9, and MPL exon 10 mutations as well as to analyze clinical characteristics associated with different mutational status in Vietnamese ET patients. Methods: We explored mutations of JAK2V617F, MPL, and CALR from 395 patients using allele specific oligonucleotide – polymerase chain reaction and Sanger sequencing techniques; then, the clinical and hematological features were compared according to mutation patterns. Results: We found that JAK2V617F, CALR exon 9, and MPL exon 10 mutations were present in 56.2%, 27.6%, and 1% of the 395 patients with ET, respectively. Twelve different types of CALR mutation were detected in 109 patients, with the CALR type 1 mutation (c.1099_1150del; L367fs*46) was the most common, followed by CALR type 2 mutation (c.1154_1155insTTGTC; K385fs*47). The JAK2V617F-positive patients had older age, higher white blood cell counts and higher hemoglobin levels but lower platelet counts than patients with CALR mutations or patients negative for triple tests. There was no significant difference regarding sex ratio, white blood cell counts, platelet counts and hemoglobin levels among CALR mutation subtypes. Conclusion: we reported high frequency of JAK2V617F, CALR, and MPL mutations in Vietnamese patients with ET and underscored the importance of combined genetic tests for diagnosis and classification of ET into different subtypes.

Indexed as

MutationAdultAgedCalreticulinFemaleFollow-Up StudiesHematologic TestsHumansJanus Kinase 2MaleMiddle AgedPrognosisReceptors, ThrombopoietinRetrospective StudiesThrombocythemia, EssentialVietnamCalreticulinCALR protein, humanJAK2 protein, humanJanus Kinase 2MPL protein, humanReceptors, ThrombopoietinCALRessential thrombocythemiaJAK2V617FMPLVietnam

Identifiers

PMID31554376
PMCPMC6976857
OpenAlexW2976472220

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.